News stories about Xencor (NASDAQ:XNCR) have been trending somewhat positive recently, according to Accern. The research firm scores the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Xencor earned a news sentiment score of 0.12 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.674440173149 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Shares of Xencor (XNCR) traded down $0.61 during mid-day trading on Friday, hitting $23.36. The stock had a trading volume of 74,533 shares, compared to its average volume of 135,111. The stock has a market cap of $1,125.65, a P/E ratio of -23.36 and a beta of 2.09. Xencor has a fifty-two week low of $18.55 and a fifty-two week high of $28.64.
Xencor (NASDAQ:XNCR) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.04). Xencor had a negative return on equity of 15.26% and a negative net margin of 148.29%. equities research analysts forecast that Xencor will post -1.1 earnings per share for the current year.
Several analysts have commented on XNCR shares. Canaccord Genuity set a $36.00 price objective on Xencor and gave the company a “buy” rating in a research note on Monday, October 23rd. Cantor Fitzgerald started coverage on Xencor in a research note on Wednesday, November 29th. They set an “overweight” rating and a $33.00 price objective for the company. Zacks Investment Research raised Xencor from a “sell” rating to a “hold” rating in a research note on Wednesday, November 22nd. Piper Jaffray Companies reissued a “buy” rating and set a $35.00 target price on shares of Xencor in a research note on Sunday, November 12th. Finally, BidaskClub raised Xencor from a “strong sell” rating to a “sell” rating in a research note on Thursday, December 7th. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. Xencor has a consensus rating of “Hold” and an average price target of $30.80.
In other news, major shareholder John S. Stafford III purchased 50,000 shares of the stock in a transaction that occurred on Thursday, November 2nd. The shares were acquired at an average price of $19.58 per share, for a total transaction of $979,000.00. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder John S. Stafford III purchased 3,400 shares of the stock in a transaction that occurred on Wednesday, November 8th. The stock was purchased at an average price of $19.89 per share, for a total transaction of $67,626.00. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 103,882 shares of company stock valued at $2,062,130. Company insiders own 4.03% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Xencor (XNCR) Receiving Somewhat Favorable Press Coverage, Study Finds” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/28/xencor-xncr-receiving-somewhat-positive-media-coverage-report-shows.html.
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.